Why nitrosamine analysis becomes challenging at trace level
Nitrosamine formation can be associated with raw materials, synthetic routes, process conditions, solvents, reagents, degradation pathways and cross-contamination. At the same time, the analytical limits involved can be extremely low.
The challenge is therefore not only detecting a compound. The analytical method must perform reliably within the specific pharmaceutical matrix.
That means considering:
- sample preparation and extraction;
- chromatographic separation;
- sensitivity and selectivity;
- matrix effects;
- recovery;
- quantitative performance;
- validation for the intended purpose.
What you will learn in the whitepaper
How to define the analytical objective
Determine the sensitivity, selectivity and quantitative range required.
How matrix complexity affects method performance
Understand why an approach that works for one API or formulation may not automatically work for another.
How LC-MS/MS supports targeted nitrosamine analysis
Learn how sample preparation, chromatography and MS parameters work together.
How to move from development to validation
See which performance characteristics need to be understood and demonstrated.
When targeted analysis may not be enough
Explore when broader analytical strategies can support investigation of unexpected impurities or results.
Download the N-nitrosamines whitepaper
N-nitrosamines: Developing scientifically defensible analytical methods
Get practical insight into nitrosamine method development, LC-MS/MS analysis, matrix effects, validation and the analytical decisions behind reliable trace-level results.
supports pharmaceutical companies across the analytical lifecycle:
From method development to routine analysis
-
1.
Method development
-
2.
Method optimisation
-
3.
Method validation
-
4.
Confirmatory testing
-
5.
Advanced screening
-
6.
Routine analysis
Have a specific matrix or analytical challenge?
FAQ
-
A method that performs well for one API or pharmaceutical formulation may not automatically be suitable for another. Matrix components can affect sample preparation, chromatographic separation, ionisation and overall analytical performance. Matrix-specific method development helps ensure that the required sensitivity, selectivity, recovery and quantitative performance can be achieved for the intended pharmaceutical application.
-
No. Achieving a low limit of quantification is important, but sensitivity alone does not demonstrate that an analytical method is fit for purpose. Specificity, selectivity, accuracy, precision, recovery, robustness, matrix effects and sample stability can also be important when demonstrating method performance.
-
Targeted analysis is generally suitable when the relevant nitrosamines are known and the analytical objective is to detect or quantify specified compounds with the required sensitivity and selectivity. The analytical strategy should take the product, matrix, required quantitative range and intended use of the method into account.
-
A broader analytical investigation may be relevant when the analytical question extends beyond predefined nitrosamines, for example following an unexpected result or when potential impurities are not yet fully understood. In these situations, the analytical strategy needs to be defined around the specific question rather than relying automatically on an existing targeted method. Normec's campaign materials position advanced screening as part of the wider analytical lifecycle alongside confirmatory testing and routine analysis.
-
Method development establishes how the analytical method should work for the specific product and analytical objective. Method validation demonstrates whether the method performs appropriately for its intended use. Relevant performance characteristics can include specificity, selectivity, linearity, range, accuracy, precision, limits of detection and quantification, recovery, robustness, matrix effects and solution or sample stability.
-
Normec Healthcare & Life Sciences supports pharmaceutical companies across the nitrosamine analytical lifecycle, including method development, method optimisation, method validation, confirmatory testing, advanced screening and routine analysis. The objective is to develop analytical approaches appropriate to the specific pharmaceutical product, matrix and analytical question.
Related services
Related Articles
15 Jul 2026
How to Become Fully Inspection-Ready According to Annex 1
What happens when inspectors enter your production environment? Do you really have everything in order? Or is there a risk that your processes will fall short at first glance? And how do you make your company inspection-proof? It starts with documentation. Unfortunately, a few neatly filed SOPs aren’t enough. Inspectors want more and are looking for evidence that your processes are robust and continuously monitored.
15 Jul 2026
Innovative Approaches to Paperless Validation
Computerized System Validation (CSV) is the way to ensure the reliability, compliance, and data integrity of automated systems in regulated industries. With the shift toward digital transformation, paperless validation methods are gaining importance. This article explores innovative approaches and technologies that streamline the CSV process while maintaining compliance and data integrity.
15 Jul 2026
Does your organization have complete control over all its processes?
Modern processes are monitored using sensors. These sensors indicate, for example, whether the product is being manufactured under the correct conditions. But can we always blindly trust the results these sensors record?
15 Jul 2026
What is risk assessment?
Risk management—that is, risk analysis and risk control—is important for every company. By conducting a risk analysis, you determine what the risks are, particularly those that threaten your business objectives. These include risks related to product quality and safety (such as (cross)contamination and mix-ups) and employee health and safety, as well as regulatory compliance. Corrective and/or preventive actions can then help reduce these risks and make them manageable. Discover the basic principles of risk management and learn how to identify, analyze, and mitigate potential risks.
15 Jul 2026
What is the essence of an effective supply chain?
In the rapidly changing world of business operations, maintaining high-quality products during distribution is crucial. Our consultants have extensive knowledge of Good Distribution Practice (GDP) and its impact on efficient business operations. GDP goes beyond mere compliance with regulations. From temperature control to smart storage and seamless transportation, it is the essence of an effective supply chain.
15 Jul 2026
What is Annex 1?
Pharmaceutical companies within the EU must operate in accordance with European laws and regulations, as described in EudraLex, Vol. 4 – Good Manufacturing Practice (GMP) guidelines. Annex 1, titled “Manufacture of Sterile Medicinal Products,” provides general guidelines to be used in the design and control of facilities, equipment, systems, and procedures used for the manufacture of sterile products.
15 Jul 2026
What if you took a completely different approach to Gowning?
When you think of gowning, you probably think of putting on protective clothing. The way employees dress in cleanrooms is key to preventing product contamination and ensures compliance with even the strictest standards related to Annex 1. A single small particle in the wrong place can make the difference between a perfect product and a lost batch.